Skip to content
Screener

SELLAS Life Sciences Group, Inc. SLS Free cash flow

Discontinued — last reported Q4 '16

Free cash flow at other companies

Pfizer logo
PfizerPFE
$2.18B+23.0%
AbbVie logo
AbbVieABBV
$3.56B+155%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$119M+10.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$77.14M+11.4%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$109.4M-102%

Other financials

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$2.3B+1,350%
Enterprise value$2.19B+1,537%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%—

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0×0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

−$8.0Mnet cash from operating=-$8M

The source filing: SELLAS Life Sciences Group, Inc.’s 10-K, filed March 15, 2017. Open the filing →

Filed
Mar 15, 2017, 4:28 PM EDT
Fiscal year
FY2016
Accession
0001390478-17-000020

FAQ

What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.